mebendazole 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
anthelminthics, tiabendazole derivatives	1641	31431-39-7

Description:

Molecule

Description

Molfile Inchi Smiles

Synonyms:

mebendazole
vermox

A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.

Molecular weight: 295.30
Formula: C16H13N3O3
CLOGP: 3.08
LIPINSKI: 0
HAC: 6
HDO: 2
TPSA: 84.08
ALOGS: -3.87
ROTB: 4

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.20	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
BA (Bioavailability)	22 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	1.20 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	15 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.09 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	1.10 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
June 28, 1974	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Exposure during pregnancy	113.18	40.62	41	378	155506	63333097

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Exposure during pregnancy	69.18	43.32	24	386	101108	79642870

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	P02CA01	ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS ANTHELMINTICS ANTINEMATODAL AGENTS Benzimidazole derivatives
ATC	P02CA51	ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS ANTHELMINTICS ANTINEMATODAL AGENTS Benzimidazole derivatives
FDA EPC	N0000175481	Anthelmintic
MeSH PA	D000871	Anthelmintics
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D050256	Antimitotic Agents
MeSH PA	D000969	Antinematodal Agents
MeSH PA	D000977	Antiparasitic Agents
MeSH PA	D050257	Tubulin Modulators
CHEBI has role	CHEBI:35444	antinematodal drugs
CHEBI has role	CHEBI:60832	tubulin modulators
CHEBI has role	CHEBI:61951	microtubule destabilizing role

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Ascariasis	indication	2435008	DOID:456
Trichuriasis	indication	3752003
Enterobiasis	indication	266162007
Ancylostoma Duodenale Infection	indication
Necator Americanus Infection	indication
Infection by Gnathostoma	off-label use	44086001	DOID:11379
Capillaria infection	off-label use	52979002	DOID:12474
Echinococcus granulosus infection	off-label use	75006000	DOID:1495
Echinococcus multilocularis	off-label use	86648009
Infection by larvae of Trichinella spiralis	off-label use	88264003
Angiostrongyliasis due to Angiostrongylus cantonensis	off-label use
Angiostrongyliasis due to Angiostrongylus costaricensis	off-label use
Disease of liver	contraindication	235856003	DOID:409

🐶 Veterinary Drug Use

Species	Use	Relation
Dogs	Treatment of infections with roundworms, Toxocara canis	Indication
Dogs	Treatment of infections with hookworms, Ancylostoma caninum	Indication
Dogs	Treatment of infections with Uncinaria stenocephala	Indication
Dogs	Treatment of infections with whipworms, Trichuris vulpis	Indication
Dogs	Treatment of infections with tapeworms, Taenia pisiformis	Indication
Horses	Treatment of infections caused by large roundworms, Parascaris equorum	Indication
Horses	Treatment of infections caused by large strongyles, Strongylus edentatus	Indication
Horses	Treatment of infections caused by large strongyles, S equinus	Indication
Horses	Treatment of infections caused by large strongyles, S vulgaris	Indication
Horses	Treatment of infections caused by small strongyles	Indication
Horses	Treatment of infections caused by 4th larval stage pinworms, Oxyuris equi	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Telmin Equine Wormer	Intervet Inc.	1
Telmin Syringe Formula	Intervet Inc.	1
Telmin B Equine Wormer	Intervet Inc.	2
Telmintic Powder	Intervet Inc.	1
Telmin	Intervet Inc.	1
Telmin B Paste	Intervet Inc.	2

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	10.61	acidic
pKa2	13.2	acidic
pKa3	2.93	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Tyrosine-protein kinase ABL1	Kinase	P00519	ABL1_HUMAN		Ki	5.34		CHEMBL
Vascular endothelial growth factor receptor 2	Kinase	P35968	VGFR2_HUMAN		IC50	5.44		CHEMBL
Tubulin	Structural		C4PKY4_ECHGR C4PKZ2_ECHGR C4PKZ6_ECHGR	INHIBITOR				CHEMBL	CHEMBL
Tubulin	Structural		F1L005_ASCSU F1L4P8_ASCSU F1L5G6_ASCSU F1L7U3_ASCSU F1L7Y0_ASCSU F1L8A5_ASCSU F1LCS0_ASCSU	INHIBITOR				CHEMBL	CHEMBL
Calmodulin-domain protein kinase 1	Kinase		Q9BJF5_TOXGO		IC50	6.17		CHEMBL

External reference:

ID	Source
4019270	VUID
N0000147469	NUI
D00368	KEGG_DRUG
4019270	VANDF
C0025023	UMLSCUI
CHEBI:6704	CHEBI
V95	PDB_CHEM_ID
CHEMBL685	ChEMBL_ID
DB00643	DRUGBANK_ID
D008463	MESH_DESCRIPTOR_UI
4030	PUBCHEM_CID
2942	INN_ID
81G6I5V05I	UNII
202972	RXNORM
1672	MMSL
5026	MMSL
789	MMSL
d00154	MMSL
002987	NDDF
387311004	SNOMEDCT_US
56059005	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
VERMOX	HUMAN PRESCRIPTION DRUG LABEL	1	50458-675	TABLET, CHEWABLE	500 mg	ORAL	NDA	28 sections
MEBENDAZOLE	HUMAN PRESCRIPTION DRUG LABEL	1	54868-3732	TABLET, CHEWABLE	100 mg	ORAL	ANDA	21 sections
Emverm	HUMAN PRESCRIPTION DRUG LABEL	1	64896-669	TABLET, CHEWABLE	100 mg	ORAL	ANDA	26 sections
Emverm	HUMAN PRESCRIPTION DRUG LABEL	1	64896-669	TABLET, CHEWABLE	100 mg	ORAL	ANDA	26 sections